Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/ G1244E

Donatello Salvatore; Carmela Colangelo; Michele D'Andria; Giovanni Marsicovetere; Domenica Passarella

doi:10.1002/ccr3.4713

Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/ G1244E

Clin Case Rep. 2021 Aug 25;9(8):e04713. doi: 10.1002/ccr3.4713. eCollection 2021 Aug.

Authors

Donatello Salvatore¹, Carmela Colangelo¹, Michele D'Andria¹, Giovanni Marsicovetere¹, Domenica Passarella¹

Affiliation

¹ Cystic Fibrosis Centre - Hospital San Carlo Potenza Italy.

Abstract

Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane regulator (CFTR) modulator. It is known to be efficacious in stable patients with severe pneumopathy, but there are few data concerning its effectiveness during acute exacerbations. We here describe its use in a woman with CF and respiratory failure.

Keywords: genetics; respiratory medicine.

Publication types

Case Reports